Thermo Fisher Scientific Inc, a global leader in scientific services, has officially announced a definitive agreement with Solventum to purchase its Purification & Filtration division for approximately $4.1 billion in cash.
Solventum’s Purification & Filtration division is a top provider of advanced purification and filtration solutions, essential in biologics production, medical technologies, and various industrial applications. Operating on a global scale, the business has facilities across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region, employing around 2,500 people. In 2024, this segment generated approximately $1 billion in revenue.
Upstream and downstream
This acquisition will enhance Thermo Fisher’s existing bioproduction portfolio. Currently, the company offers leading solutions in cell culture media and single-use technologies. By integrating Solventum’s innovative filtration solutions, Thermo Fisher will expand its capabilities in biologics development and manufacturing, covering both upstream and downstream processes. “The addition of Solventum’s business is an outstanding strategic fit with our company and will create significant value for our customers and shareholders,” stated Marc N. Casper, chairman, president, and chief executive officer of Thermo Fisher. “Solventum’s portfolio of solutions will be valued by our customers, and further demonstrate our disciplined capital deployment strategy which has an excellent track record of creating shareholder value.”
Bioprocessing portfolio
Casper further added, “As the trusted partner to our customers, Solventum’s Purification & Filtration business will expand and add differentiated capabilities to our bioprocessing portfolio to better serve our customers in this rapidly growing market. We look forward to welcoming our new colleagues to Thermo Fisher.”
The deal is anticipated to close by the end of 2025, pending regulatory approvals and standard closing conditions. Upon completion, Solventum’s Purification & Filtration business will be integrated into Thermo Fisher’s Life Sciences Solutions segment.